

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: www.sunpharma.com  
CIN: L24230GJ1993PLC019050



March 23, 2022

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**NSE Code: SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Stock Code: 524715**

**Sub.: Disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015, as amended (“Listing Regulations”) - Signing of Binding Memorandum of Understanding as to Material Terms of Settlement (“Binding Term Sheet”) with the Direct Purchaser and End-Payor Plaintiffs in the In re Ranbaxy Generic Drug Application Antitrust Litigation in the U.S. District Court for the District of Massachusetts (USA).**

Dear Sir / Madam,

Pursuant to the requirements under Regulation 30 of the Listing Regulations, this is to inform you that Sun Pharmaceutical Industries Ltd. and one of its U.S. based subsidiaries, Ranbaxy, Inc. (hereinafter, collectively referred to as the “Company”), have signed a Binding Term Sheet with two plaintiff groups, the Direct Purchaser and End-Payor Plaintiffs, collectively resolving all of the claims against the Company, in the matter In re Ranbaxy Generic Drug Application Antitrust Litigation that has been ongoing in the U.S. District Court for the District of Massachusetts (USA) for several years.

In the matter of In re Ranbaxy Generic Drug Application Antitrust Litigation, there were multiple antitrust, consumer protection, and civil RICO class actions consolidated in the District of Massachusetts, (USA) against the Company in connection with generic Diovan®, a drug for the treatment of hypertension; generic Nexium®, a drug for the treatment of gastroesophageal reflux disease and peptic ulcers; and generic Valcyte®, a drug for the treatment of cytomegalovirus disease. The actions / claims relate to alleged conduct by Ranbaxy Laboratories Ltd. and its U.S. subsidiary prior to its acquisition by Sun Pharmaceutical Industries Ltd. The Company has disputed the claims of the plaintiffs and defended these matters vigorously.

With a view to resolve this dispute and avoid uncertainty, the Company has agreed to enter a comprehensive settlement with these plaintiff groups for a total settlement amount of US\$ 485 million (US Dollar Four Hundred and Eighty Five million).

**Page 1 of 2**

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: www.sunpharma.com  
CIN: L24230GJ1993PLC019050



As a consequence of the Binding Term Sheet, the Company shall execute the necessary settlement agreements, which, upon approval by the U.S. Court, will ensure that all allegations against the Company, which it has denied, not conceded and not admitted, do not survive and stand extinguished.

This is for your information and dissemination.

Your's faithfully,  
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**